Sagent voluntarily recalls phenylephrine hydrochloride vials

The company is recalling 10 mg/mL vials of phenylephrine hydrochloride due to potential lack of sterility assurance in several lots of the product.
Sagent Pharmaceuticals has announced the voluntary US-wide recall of three lots of Phenylephrine Hydrochloride Injection, USP (10 mg/mL). Recall of the product (manufactured by Indoco Remedies and distributed by Sagent) was initiated by Sagent after hearing customer complaints about potentially loose crimped vial overseals; a non-integral crimped vial overseal may result in a non-sterile product.
According to the US Food and Drug Administration (FDA), intravenous administration of a product intended to be sterile that is not actually sterile could result in serious systemic infections, which could end up being life-threatening. To date, Sagent has not received reports of any adverse events associated with this issue.

Related Keywords

, Fedex , Drug Administration , Sagent Pharmaceuticals , Phenylephrine Hydrochloride Injection , Indoco Remedies , Hydrochloride Injection , Markets Amp Regulations , Drug Delivery , Contract Manufacturing Amp Logistics , Patient Centricity , Regulations , Regulatory Affairs , Supply Chain , Logistics , Fda , Recall , Vials , Injectables , Regulation , ஃபெடெக்ஸ் , சகெண்ட் மருந்துகள் , சந்தைகள் ஆம்ப் ஒழுங்குமுறைகள் , மருந்து டெலிவரி , ஒப்பந்த உற்பத்தி ஆம்ப் தளவாடங்கள் , ஒழுங்குமுறைகள் , ஒழுங்குமுறை வாழ்க்கைத்தொழில்கள் , விநியோகி சங்கிலி , தளவாடங்கள் , ஃப்ட , ரீகால் , ஊசி மருந்துகள் , ஒழுங்குமுறை ,